Abbott Laboratories

Stories

FDA clears first wearable that monitors both glucose and ketones

Device developer and commercial sponsor

The FDA on August 25 authorized Abbott's Libre Duo 10 Day, the first wearable that continuously tracks both blood sugar and ketone levels in a single sensor. The device samples the fluid just beneath the skin every minute for up to 10 days, for people as young as 2.

Updated Aug 26

Abbott absorbs Exact Sciences, creating a cancer diagnostics giant

Money Moves

Acquirer

Abbott Laboratories closed its $21 billion acquisition of Exact Sciences on March 23, making the maker of the Cologuard colorectal cancer screening test a wholly owned subsidiary of one of the world's largest healthcare companies. The all-cash deal, at $105 per share, passed through antitrust review without a second request from regulators—a sign of how little the two companies' product lines overlapped before this combination.

Updated May 30